Send the following on WhatsApp
Continue to ChatBevacizumab (BEV) plus capecitabine as maintenance therapy after initial treatment with BEV plus XELOX in previously untreated patients (pts) with metastatic colorectal cancer (mCRC): Mature data from STOP and GO, a phase III, randomized, multicenter study - https://avesis.gazi.edu.tr/yayin/69d5f151-f3c8-48f7-ac1e-a95e70488d98/bevacizumab-bev-plus-capecitabine-as-maintenance-therapy-after-initial-treatment-with-bev-plus-xelox-in-previously-untreated-patients-pts-with-metastatic-colorectal-cancer-mcrc-mature-data-from-stop-and-go-a-phase-iii-randomized-multicenter-study